DYNE THERAPEUTICS INC. - COMMON STOCK

13,72

24-января-25 16:45:00

15 мин. задержка

Акции

+0,03

+0,22%

Сегодняшний диапазон

13,45 - 14,51

ISIN

N/A

Источник

NASDAQ

Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

02 май 2024 16:10:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer

27 мар 2024 16:05:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium

27 мар 2024 08:30:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Announces CEO Transition

25 мар 2024 07:30:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days

13 мар 2024 07:30:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

05 мар 2024 07:30:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference

14 фев 2024 16:15:16 Источник Nasdaq GlobeNewswire
Dyne Therapeutics to Present at February Investor Conferences

01 фев 2024 07:30:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

11 янв 2024 16:05:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

05 янв 2024 07:30:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock

04 янв 2024 22:46:36 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Announces Proposed Public Offering of Common Stock

03 янв 2024 16:25:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE™ Platform in Developing Therapeutics for Rare Muscle Diseases

03 янв 2024 06:30:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics to Host Virtual Event Tomorrow, January 3 at 8:00 AM ET, to Present Initial Clinical Data from ACHIEVE and DELIVER Trials

02 янв 2024 16:05:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics to Present at November Investor Conferences

07 ноя 2023 07:30:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Reports Third Quarter 2023 Financial Results and Provides Update on Significant Progress for ACHIEVE and DELIVER Trials and Upcoming Clinical Milestones

30 окт 2023 07:30:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics to Present at October Investor Conferences

28 сен 2023 07:30:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

20 сен 2023 16:05:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference

05 сен 2023 07:30:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

03 авг 2023 07:30:00 Источник Nasdaq GlobeNewswire

<<
<
1
2
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.